Effects of Rasagiline Combined with Levodopa and Benserazide Hydrochloride on Motor Function and Homocysteine and IGF-1 Levels in Elderly Patients with Parkinson's Disease

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2023 Oct 6

PMID 37803329

Authors

Yifan Yang

Feng Gao

Li Gao

Jiaodan Miao

Affiliations

Soon will be listed here.

Abstract

Background: During the course of their illness, people with Parkinson's disease may see changes in their insulin-like growth factor (IGF-1) and serum homocysteine (Hcy) indices. In this study, patients with intermediate to severe Parkinson's disease were examined for how Resagiline and levodopa and benserazide hydrochloride affected their motor performance, serum levels of homocysteine (Hcy), and insulin-like growth factor (IGF-1).

Methods: From June 2020 to December 2021, a total of 100+ cases of Parkinson's patients over 60 years old in the middle and late stages of Parkinson's were seen in the outpatient and inpatient departments of the Third People's Hospital of Chengdu City and had a detailed observation record, and according to the inclusion criteria, the patients who met the criteria were randomly grouped into a clinical observation group and a control group. The subjects in the control group received only levodopa and benserazide hydrochloride treatment, while the observation group was treated with Resagiline in combination with the clinical control group. The total treatment observation period was 1 year for both groups, and the motor function and serum Hcy and IGF-1 indexes of both groups were compared after the end of treatment.

Results: We randomly and evenly grouped 64 patients who met the requirements of the inclusion criteria into a clinical observation group and a control group, each with 32 patients, from among 168 patients over 60 years of age with detailed observation records in the middle and late stages of Parkinson's. After the 1-year observation period, we found that the total effective rate after treatment in the clinical observation group (93.75%) and significantly higher than that in the control group (68.75%) (P < 0.05); after 1 year of treatment, the UPDRS score decreased in both groups, and the observation group was significantly lower than the control group (P < 0.05); after treatment, serum Hcy decreased and IGF-1 increased in both groups, and the observation group was higher than the control group mean values (P < 0.05).

Conclusions: In patients with Parkinson's disease who are in the middle and late stages of the disease, the administration of Resagiline combined with levodopa and benserazide hydrochloride can significantly lower the body's serum Hcy level, significantly raise IGF-1 levels, and significantly improve motor function in patients with Parkinson's disease. It can also have significant therapeutic effects.

Citing Articles

Enhancements in Parkinson's Disease Management: Leveraging Levodopa Optimization and Surgical Breakthroughs.

Sharma R, Kour A, Dewangan H Curr Drug Targets. 2024; 26(1):17-32.

PMID: 39350551 DOI: 10.2174/0113894501319817240919103802.

Benserazide, a cystathionine beta-synthase (CBS) inhibitor, potentially enhances the anticancer effects of paclitaxel via inhibiting the S-sulfhydration of SIRT1 and the HIF1-α/VEGF pathway.

Zhao W, Feng S, Wang J, Zhang Z, Chen L, Jiang L Front Pharmacol. 2024; 15:1404532.

PMID: 38828455 PMC: 11143879. DOI: 10.3389/fphar.2024.1404532.

Role of the Insulin-like Growth Factor System in Neurodegenerative Disease.

Lewitt M, Boyd G Int J Mol Sci. 2024; 25(8).

PMID: 38674097 PMC: 11049992. DOI: 10.3390/ijms25084512.

References

Wallert E, van de Giessen E, Knol R, Beudel M, de Bie R, Booij J . Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders. J Nucl Med. 2022; 63(Suppl 1):27S-32S. PMC: 9165729. DOI: 10.2967/jnumed.121.263197. View

Zhang Z, Roman G, Hong Z, Wu C, Qu Q, Huang J . Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005; 365(9459):595-7. DOI: 10.1016/S0140-6736(05)17909-4. View

Politis M . Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014; 10(12):708-22. DOI: 10.1038/nrneurol.2014.205. View

Mehanna R, Wilson K, Cooper S, Machado A, Fernandez H . Clinical and programming pattern of patients with impending deep brain stimulation power failure: a retrospective chart review. J Clin Mov Disord. 2016; 1:6. PMC: 4677734. DOI: 10.1186/2054-7072-1-6. View

Nagy A, Garzuly F, Kalman B . [Pathogenic alterations within the neurofibromin gene in various cancers]. Magy Onkol. 2017; 61(4):327-336. View

Youn J, Lee C, Oh E, Park J, Kim J, Kim H . Genetic variants of PARK genes in Korean patients with early-onset Parkinson's disease. Neurobiol Aging. 2018; 75:224.e9-224.e15. DOI: 10.1016/j.neurobiolaging.2018.10.030. View

de Baat C, van Stiphout M, Lobbezoo F, van Dijk K, Berendse H . [Parkinson's disease: pathogenesis, aetiology, symptoms, diagnostics, and its course]. Ned Tijdschr Tandheelkd. 2018; 125(10):509-515. DOI: 10.5177/ntvt.2018.10.18176. View

Zoccolella S, Lamberti P, Iliceto G, DellAquila C, Diroma C, Fraddosio A . Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clin Chem Lab Med. 2006; 44(7):863-6. DOI: 10.1515/CCLM.2006.143. View

Camicioli R, Bouchard T, Somerville M . Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov Disord. 2008; 24(2):176-82. DOI: 10.1002/mds.22227. View

10.

Picillo M, Erro R, Santangelo G, Pivonello R, Longo K, Pivonello C . Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. J Neurol. 2013; 260(7):1724-30. DOI: 10.1007/s00415-013-6851-0. View

11.

Cassilhas R, Antunes H, Tufik S, de Mello M . Mood, anxiety, and serum IGF-1 in elderly men given 24 weeks of high resistance exercise. Percept Mot Skills. 2010; 110(1):265-76. DOI: 10.2466/PMS.110.1.265-276. View

12.

Baldini S, Restani L, Baroncelli L, Coltelli M, Franco R, Cenni M . Enriched early life experiences reduce adult anxiety-like behavior in rats: a role for insulin-like growth factor 1. J Neurosci. 2013; 33(28):11715-23. PMC: 6618685. DOI: 10.1523/JNEUROSCI.3541-12.2013. View

13.

Kao S . Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors. Biochem Biophys Res Commun. 2009; 385(3):434-8. DOI: 10.1016/j.bbrc.2009.05.089. View

14.

Boland D, Stacy M . The economic and quality of life burden associated with Parkinson's disease: a focus on symptoms. Am J Manag Care. 2012; 18(7 Suppl):S168-75. View

15.

Klivenyi P, Vecsei L . [The treatment of advanced Parkinson's disease]. Ideggyogy Sz. 2019; 71(11-12):377-383. DOI: 10.18071/isz.71.0377. View

16.

Hauser R, Li R, Perez A, Ren X, Weintraub D, Elm J . Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis. 2016; 7(1):117-127. DOI: 10.3233/JPD-160965. View

17.

Jenner P, Langston J . Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord. 2011; 26(13):2316-23. DOI: 10.1002/mds.23926. View

18.

Robottom B . Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. Patient Prefer Adherence. 2011; 5:57-64. PMC: 3058602. DOI: 10.2147/PPA.S11182. View

19.

Cai J, Chen W, Lin Y, Cai B, Wang N . Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials. Eur Neurol. 2014; 73(1-2):5-12. DOI: 10.1159/000367892. View

20.

Hornykiewicz O, Kish S . Biochemical pathophysiology of Parkinson's disease. Adv Neurol. 1987; 45:19-34. View